The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Sequenom's revenues will expand 68.7% and EPS will remain in the red.
The average estimate for revenue is $22.9 million. On the bottom line, the average EPS estimate is -$0.23.
Last quarter, Sequenom recorded revenue of $18.3 million. GAAP reported sales were 37% higher than the prior-year quarter's $13.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.26. GAAP EPS were -$0.26 for Q2 versus -$0.21 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 32.2%, 3,460 basis points worse than the prior-year quarter. Operating margin was -160.2%, 300 basis points worse than the prior-year quarter. Net margin was -162.3%, 520 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $84.8 million. The average EPS estimate is -$0.92.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 670 members out of 726 rating the stock outperform, and 56 members rating it underperform. Among 152 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 137 give Sequenom a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sequenom is outperform, with an average price target of $6.90.
- Add Sequenom to My Watchlist.